Key result
Transdermal clonidine normalized diastolic blood pressure (<90 mm Hg) in 64% of patients with mild essential hypertension over a three-month period.
Why the study?
Does transdermal clonidine reduce diastolic BP in patients with mild essential hypertension?
Does transdermal clonidine reduce diastolic BP in patients with mild essential hypertension?
Transdermal clonidine patches effectively lower and sustain diastolic blood pressure reductions in patients with mild essential hypertension over a 3-month period.
May support short-term BP control in mild hypertension; leaves open need for RCTs to confirm efficacy.
The effectiveness of transdermally administered clonidine hydrochloride was evaluated in a multicenter study in 85 patients with mild essential hypertension. The drug was incorporated into small self-adhesive delivery systems (pliable skin patches, 3.5-sq-cm area) designed to continuously deliver 0.1 mg of clonidine hydrochloride per day. These devices were changed by the patients themselves at weekly intervals. Diastolic BP fell by at least 10% in 37 patients and was normalized (less than 90 mm Hg) in 54 patients (64%); 17 of these responding patients required only one skin patch, 27 required two, and the other ten responders required three. The antihypertensive action of the transdermal clonidine was sustained for the full three months of study. Side effects were similar to those during conventional oral treatment, but appeared to be milder.
No takes yet. Share an insight, caveat, or question.
Michael A. Weber (1984) studied Mild essential hypertension (n=85). Transdermal clonidine hydrochloride was evaluated on Normalization of diastolic BP (less than 90 mm Hg). Transdermal clonidine normalized diastolic blood pressure (<90 mm Hg) in 64% of patients with mild essential hypertension over a three-month period.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: